Vaccibody listed on NOTC

Vaccibody AS announces that it will register on the Norwegian OTC-list (“NOTC”), owned and operated by Oslo Børs, from  January 27. Vaccibody will trade under the ticker “VACC”. Read...

Vaccibody announces positive clinical trial results

Vaccibody has announced strong preliminary data from the ongoing VB N-01 phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine. The data is from the first 16 patients assessed for safety after treatment with a VB10.NEO, and the first 14 patients...

Rallybio acquires Prophylix´ rare disease programs

Prophylix AS has just announced that the company in late June 2019 entered into a definitive agreement with Rallybio, a U.S.-based drug development company. Through the agreement Rallybio acquires two orphan drug programs from Prophylix AS, NAITgam and a follow-on...